Q-omics provides the consensus-scored PAK6 profile across patient tissues and cancer cell-line models. PAK6 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PAK6 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PAK6 RNA expression shows 18,501 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight COAD, KIRC, and UVM as cancer lineages where PAK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PAK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PAK6 survival associations across molecular data types. PAK6 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PAK6 RNA expression–survival associations across cancer types. High PAK6 expression shows unfavorable associations in COAD, BRCA, KIRC, SKCM and UVM, but favorable associations in ACC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for PAK6 RNA expression.
This table summarizes PAK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for PAK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PAK6 shows lower tumor expression in KIRC, KIRP and THCA and higher tumor expression in LUAD, COAD and LUSC. The KIRC box plot shows higher PAK6 RNA expression in normal versus tumor tissue (log2 FC = −0.570, t-test p < 0.001).
This table shows molecular features associated with PAK6 in patient tissues and cancer cell lines. In patient samples, PAK6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, PAK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BONE.
